Prevalence and Characteristics of Multinucleoside-Resistant Human Immunodeficiency Virus Type 1 among European Patients Receiving Combinations of Nucleoside Analogues

• DOI: 10.1128/aac.44.8.2109-2117.2000
• Publication Date: 2002-07-27T10:06:42Z
• Authors: Kristien Van Vaer...; Kristel Van Laethem; Jan Albert; Charles A. B. Bou...; Bonaventura Clotet; Marco Floridia; Jan Gerstoft; Bo Hejdeman; Claus Nielsen; Christophe Pannec...; Luc Perrin; Maria F. Pirillo; Lidia Ruiz; Jean-Claude Schmit; François Schneider; Anne Schoolmeester; Rob Schuurman; Hans J. Stellbrink; Lieven Stuyver; Jan Van Lunzen; Barbara Van Remoo...; Eric Van Wijngaerden; Stefano Vella; Myriam Witvrouw; Sabine Yerly; Erik De Clercq; Jan Desmyter; Anne-Mieke Vandamme
• Keywords: Didanosine; Zalcitabine; Stavudine; Nucleoside analogue; Reverse-transcriptase inhibitor; Resistance mutation

The prevalence and the genotypic phenotypic characteristics of multinucleoside-resistant (MNR) human immunodeficiency virus type 1 (HIV-1) variants in Europe were investigated a multicenter study that involved centers nine European countries. Study samples (n = 363) collected between 1991 1997 from patients exposed to two or more nucleoside analogue reverse transcriptase inhibitors (NRTIs) 274 control no one NRTI screened for marker mutations multinucleoside resistance (the Q151M mutation with 2-amino-acid insertion at codon 69, T69S-XX). was identified six (1. 6%), T69S-XX (0.5%; both them T69S-SS), but patterns absent among samples. Non-NRTI (NNRTI)-related changes observed viral strains patients, which displayed pattern, although NNRTI naive. whose isolates had received treatment zidovudine either didanosine, zalcitabine, stavudine. Both conferred broad cross-resistance NRTIs vitro poor response vivo. MNR HIV-1 is found only multinucleoside-experienced patients. Its low Europe, it should be closely monitored since seriously limits options.